Primary Site >> Biliary tract Cancer
Gene >> IDH2
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. PMID: 22180306 |
Ref: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. PMID: 22824796 Ref: Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. PMID: 23318457 Ref: Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. PMID: 24185513 |
Ref: Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. PMID: 24478380 Ref: Genomic and transcriptional alterations of cholangiocarcinoma. PMID: 24532422 Ref: Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. PMID: 24569570 Ref: The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. PMID: 24880135 Ref: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. PMID: 24889489 Ref: Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. PMID: 25043045 Ref: IDH mutations in liver cell plasticity and biliary cancer. PMID: 25485496 |
Ref: Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. PMID: 25481493 Ref: Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. PMID: 26245674 Ref: Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. PMID: 26260902 Ref: Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas. PMID: 26320466 |
Ref: Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. PMID: 26405193 Ref: Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. PMID: 26819452 Ref: Maffucci syndrome and neoplasms: a case report and review of the literature. PMID: 26920730 Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. PMID: 27102149 Ref: Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. PMID: 27231123 Ref: Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma. PMID: 27595804 Ref: IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. PMID: 27621679 |
Ref: Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development. PMID: 28375741 Ref: Emerging molecular therapeutic targets for cholangiocarcinoma. PMID: 28389139 Ref: Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. PMID: 28431889 Ref: Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. PMID: 28601826 Ref: Current biologics for treatment of biliary tract cancers. PMID: 28736630 Ref: New Horizons for Precision Medicine in Biliary Tract Cancers. PMID: 28818953 Ref: Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients. PMID: 28900470 |
Ref: Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. PMID: 29274619 Ref: Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. PMID: 29353494 Ref: Emerging molecular target antagonists for the treatment of biliary tract cancer. PMID: 29468924 Ref: Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update. PMID: 29776636 Ref: Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1. PMID: 30156013 Ref: Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type. PMID: 30158952 Ref: The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. PMID: 30206411 |